EGFR and non-small cell lung carcinoma: To date, amivantamab, with or without chemotherapy, has seen some success in this scenario (such as in the CHRYSALIS study [30]), but at present overcoming third-generation EGFR-TKI resistance remains a significant challenge in NSCLC treatment.